At least three recurrent chromosomal translocations, t(11;18)(q21;q21), t(1;14)(p22;q32), t(14;18)(q32;q21), involving the API2-MALT1 fusion protein, BCL10 and MALT1, have been implicated in the pathogenesis of mucosa-associated lymphoid tissue (MALT) lymphoma. Several lines of evidence indicated that both BCL10 and MALT1 are required for nuclear factor kappa B (NF-jB) activation by antigen receptor stimulation in lymphocytes, and API2-MALT1 can bypass this BCL10/MALT1 signaling pathway. Nuclear factor kappa B activation may contribute to antiapoptotic effect through NF-jB-mediated upregulation of apoptotic inhibitor genes. We recently demonstrated that API2-MALT1 can induce transactivation of the API2 gene through NF-jB activation, thus highlighting a positive feedback-loop mechanism of self-activation by upregulating its own expression in t(11;18) MALT lymphomas. We also demonstrated that API2-MALT1 possesses an antiapoptotic effect, in part, through its direct interaction with apoptotic regulators. These findings therefore led us to hypothesize that the antiapoptotic effect by API2-MALT1 may be mediated by its interaction with apoptotic regulators, on the one hand, and by NF-jB-mediated upregulation of apoptotic inhibitor genes on the other. We also found that BCL10 and MALT1 are shuttling between nucleus and cytoplasm, and that MALT1 can regulate the subcellular location of BCL10. Leukemia (2006) 20, 929-936.
Mucosa-associated lymphoid tissue lymphoma
In 1983, Issacson and Wright 1 first observed that the histology of extranodal lymphomas was similar to that of mucosa-associated lymphoid tissue (MALT) rather than that of peripheral lymph nodes. This lymphoma is now recognized and defined as a distinct clinicopathological disease entity in the category of extranodal marginal zone lymphomas of MALT type in the revised European-American classification of lymphoid neoplasms and the recently published World Health Organization classification of malignant lymphomas. 2, 3 Mucosa-associated lymphoid tissue lymphoma is also characterized by an indolent clinical course and characteristic histological appearance including lymphoepithelial lesions and follicular colonization. [4] [5] [6] [7] Most of MALT lymphomas occur in organs normally containing no lymphoid tissue, such as stomach, salivary gland, lung, thyroid and ocular adnexa. [4] [5] [6] [7] Chronic inflammation, such as Helicobacter pylori in gastritis and autoimmune diseases, may significantly contribute to the pathogenesis of this lymphoma. Among MALT lymphomas, gastric MALT lymphoma is the most common and most thoroughly studied subtype. 8 H. pylori infection is observed in most cases of gastric MALT lymphomas. [9] [10] [11] [12] [13] In in vitro experiments, H. pylori-specific activated T cells were found to stimulate the growth of gastric MALT lymphoma cells. 14, 15 These experiments are supported by the fact that the eradication of H. pylori results in regression of gastric MALT lymphoma in approximately 70% of gastric MALT lymphoma cases. 16, 17 The importance of antigen stimulation in MALT lymphomagenesis is supported by several analytical studies of the Ig-heavy-chain (IgH) gene, which demonstrated the ongoing mutation of IgH gene and the preferential use of VH genes commonly detected in autoimmune diseases. [18] [19] [20] [21] [22] [23] Several lines of evidence thus suggest that MALT lymphomas are antigen-driving clonal B-cell lymphomas.
Molecular genetics of mucosa-associated lymphoid tissue lymphomas
The molecular genetics underlying the pathogenesis of MALT lymphomas are only recently beginning to be understood. A number of genetic alterations have been identified in MALT lymphoma, including trisomies of chromosomes 3, 7, 12 and 18, p53 mutations, p16 deletion and recurrent chromosomal translocations including t(11;18)(q21;q21), t(1;14)(p22;q32), t(14;18)(q32;q21) and t(3;14)(p14.1;q32). [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] Whole or partial trisomy 3 has been detected in about 60% of MALT lymphomas. 27, 29, 30 Other trisomies, such as trisomies 7, 12 and 18, were observed non-randomly, 5, 28, 30 but less frequently than trisomy 3. The recurrent translocations, t(11;18)(q21;q21), t(1;14)(p22;q32) and t(3;14)(p14.1;q32), have been found exclusively in MALT lymphoma at various frequencies of about 30, 11-18 and 3%, respectively. 28, 32, 34, [36] [37] [38] [39] [40] [41] [42] [43] The t(11;18) translocation occurs at various frequencies depending on the site of tumor origin; lung (38%), stomach (24%), conjunctiva (19%) and orbit (14%). 44 Mucosa-associated lymphoid tissue lymphomas with t(11;18) tend to gain autonomous growth and do not respond to H. pylori eradication, but rarely develop into high-grade tumors, whereas those with t(1;14) are probably H. pylori-independent and may develop into high-grade tumor. t(14;18) translocation has only rarely been found in MALT lymphomas of the gastrointestinal tract or lung. Mucosaassociated lymphoid tissue lymphomas without these translocations, often carrying trisomies of chromosomes 3, 7, 12 and 18, respond to H. pylori eradication, but they often transform into high-grade tumor following inactivation of the p53 and p16 genes. Several genes located at chromosome 3 have been proposed as possibly responsible for these alterations, including BCL6 and FOXP1. 31, 40, [45] [46] [47] [48] Given that the BCL6 gene is involved in diffuse large B-cell lymphomas, it is possible that this gene also contributes to the pathogenesis of other lymphomas with trisomy 3, but the actual target gene in MALT lymphoma with trisomy 3 has not yet been identified. Recently, p16 gene methylation was detected in 60% of MALT lymphoma cases, and it was also suggested that p16 methylation is not associated with tumor progression, but may be an early event in MALT lymphomagenesis. 49 In addition, mutations in the FAS gene were also found at a high frequency (60%) in MALT lymphoma. 50 FAS is a mediator of cell death in the germinal center B cells, which suggests that its inactivation may be involved in the pathogenesis of MALT lymphoma.
As mentioned above, four recurrent chromosomal translocations, t(11;18)(q21;q21), t(1;14)(p22;q32), t(14;18)(q32;q21) and t(3;14)(p14.1;q32), have been implicated in the pathogenesis of MALT lymphoma. The first three involve, respectively, the API2-MALT1 fusion protein, BCL10 and MALT1. 36, 37, 39, [51] [52] [53] [54] These three chromosomal translocations that involve different oncogenes thus utilize a common signaling pathway by ultimately targeting the same nuclear factor kappa B (NF-kB) signaling pathway [54] [55] [56] [57] [58] [59] ( Figure 1 ). (1) t(11;18)(q21;q21) has been reported as one of the most frequently occurring chromosomal translocations in MALT lymphomas (about 30%). 34, 35 We as well as others provide evidence that this aberration results in the fusion of two genes, the API2 at 11q21 and the novel gene, MALT1 at 18q21, generating the API2-MALT1 fusion protein. [51] [52] [53] API2 is an inhibitor belonging to the apoptosis protein (IAP) gene family, which includes X-IAP, API1 (c-IAP1) and ML-IAP, and has three Baculovirus IAP Repeat (BIR) domains, one CAspase Recruitment Domain (CARD) and one RING finger domain. The C-terminal RING domain of APIs is known to exert ubiquitin ligation activity. 60, 61 MALT1 is a novel protein that contains a death domain, two immunoglobulin-like domains and a caspase-like domain (CLD). It was demonstrated that BCL10 and MALT1 form a strong complex and these two proteins synergize in NF-kB activation. 54, 55 The generation of BCL10-deficient mice resulted in defective B-cell receptor-and T-cell receptor (TCR)-induced NF-kB activation and cell proliferation, 62, 63 whereas the studies of MALT1-deficient mice provided evidence that MALT1 is essential for T-cell activation, proliferation and interleukin (IL)-2 production in response to TCR stimulation and is required for NF-kB activation induced by the TCR. 64, 65 Taken together, these results suggest that both BCL10 and MALT1 link antigen receptor signaling to NF-kB activation.
Other groups as well as ours found that there are four breakpoints in the API2 portion and four in the MALT portion in cases with t(11;18). [41] [42] [43] All of them are fused in-frame and constitute a total of eight variant forms of the fusion transcripts, all of which always contain three BIR domains in the API2 portion and a CLD in the MALT1 portion. We also examined the stability of transiently expressed API2, MALT1 and API2-MALT1 by using immunoblot analysis of the cell lysates treated or not treated with MG132, a proteasome inhibitor. 66 This analysis disclosed that MALT1 is rapidly degraded via the ubiquitinproteasome pathway, as is the case with API2. Upon the fusion synthesis, API2-MALT1 became readily detectable even without treatment with MG132, suggesting that the fusion protein becomes stable against the ubiquitin-proteasome pathway. Thus, the increased stability of this fusion protein can be expected to result in inappropriate NF-kB activation.
t(11;18) translocation was found to be significantly associated with infection of cagA-positive strains of H. pylori. 44 It has been suggested that the occurrence of this translocation may be due to direct DNA damage mediated by oxidative reactive species generated by neutrophils. Liu et al. 67, 68 examined the prognostic value of t(11;18)(q21;q32) in gastric MALT lymphomas treated with H. pylori eradication, and demonstrated that MALT lymphomas with t(11;18) do not respond to such H. pylori eradication. We also established that the presence of t(11;18) is significantly correlated with unresponsiveness to H. pylori eradication. 69, 70 Detection of this translocation thus has significant implication for the treatment of patients with gastric MALT lymphomas.
(2) t(1;14)(p22;q32) occurs in approximately 3% of MALT lymphomas, which tend to be at an advance stage. The BCL10 gene was isolated from the breakpoint of the t(1;14) translocation in MALT lymphomas 36, 37 in which the entire BCL10 gene at 1p22 is juxtaposed to the IgH gene enhancer at 14q32, thereby resulting in the deregulated expression of BCL10. This protein was initially shown to be proapoptotic, 36 which was also isolated as a CARD-containing protein, with the aid of the protein database searches. [71] [72] [73] [74] The CARD motif is found in a number of apoptotic regulatory proteins and allows for both homo-and heterodimerization of the CARD-containing proteins. Overexpression of BCL10 activates the I-kB kinase (IKK) complex through CARD domain-mediated self-oligomerization, resulting in NF-kB activation. 75 In line with these findings, a recent in vitro study indicated that BCL10 could prevent immature B-cell line from antigen receptor-induced apoptosis. 76 Figure 1 Molecular mechanisms underlying the pathogenesis of mucosa-associated lymphoid tissue (MALT) lymphomas with t(11;18), t(1;14) and t(14;18) translocations. Antigen stimulation and CD40 triggering synergize in nuclear factor kappa B (NF-kB) activation through formation of CARMA1-BCL10-MALT1 ternary complex. BCL10 induces the oligomerization of MALT1, and activated MALT1 then induces the ubiquitination of NEMO, thereby ultimately leading to NF-kB activation. It remains to be determined whether TRAF6 binds to the activated MALT1 and functions as a ubiquitin ligase for NEMO. In t(1;14) or t(14;18) MALT lymphoma cells, deregulated expression of BCL10 or MALT1 induces the ubiquitination of NEMO, resulting in NF-kB activation. In t(11;18) MALT lymphoma cells, API2-MALT1 can bypass the normal BCL10-MALT1 signaling pathway, resulting in NFkB activation. Induced NF-kB activation might contribute to expression of the target genes, including both API2 and API2-MALT1 fusion genes, resulting in the enhancement of antiapoptotic effect through a positive feedback-loop pathway. Conversely, API2-MALT1 can exert an antiapoptotic effect through its direct interaction with apoptotic regulators, including Smac. It can thus be hypothesized that the antiapoptotic effect by API2-MALT1 may be mediated through two signaling pathways: one mediated by its interaction with apoptotic regulators, and the other mediated by the upregulation of apoptotic inhibitor genes.
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The two studies examined whether BCL10 transgenic mice can generate B-lymphocyte proliferative disorders; one recent study showed that the transgenic mice using prion promoter exhibit the enhanced apoptosis of T and B cells and atrophy of the thymus and spleen, 77 whereas another study demonstrated that the mice using Ig enhancer developed splenomegaly owing to a marked increase in splenic marginal zone B cells. 78 The BCL10 protein is expressed predominantly in the cytoplasm of germinal center B cells, 79 whereas this protein is found to be strongly expressed in the nucleus of MALT lymphomas with t (1;14) . 79 Moderate nuclear expression of BCL10 is also observed in nearly 100% of MALT lymphomas with the other translocation, t(11;18) . [80] [81] [82] On the basis of these findings, it has been suggested that the aberrant nuclear expression of BCL10 may be involved in the pathogenesis of MALT lymphoma.
(3) The third translocation, t(14;18)(q32;q21), involving the IgH gene promoter at 14q32 and the MALT1 gene at 18q21, has recently been reported. 38, 39, 83, 84 In vitro experiments suggested that MALT1 alone does not induce NF-kB activation, but it can synergize with BCL10 in NF-kB activation. 54, 55 Consistent with this finding, strong cytoplasmic expressions of both MALT1 and BCL10 have been observed in MALT lymphomas with t(14;18). It can be speculated that these strong cytoplasmic expressions can be explained by stabilization of BCL10 in the cytoplasm resulting from overexpressed MALT1 in MALT lymphomas with t(14;18). Two recent studies examined the incidence of t(14;18) in MALT lymphoma. The first study found the translocation in the liver (4/4), skin (3/11), ocular adnexa (3/8) and salivary gland (2/11) but not in the gastrointestinal tract (19) , lung (7), thyroid (4) and breast (2) , and the second study identified this translocation in 3/27 (11%) pulmonary MALT cases. 38, 39 In addition to chromosomal rearrangements, the MALT1 gene appears to be deregulated by gene amplification in two cell lines out of 40 B-non-Hodgkin's lymphoma (NHL) cell lines. 83 These data implicate MALT1 as a dominant oncogene that may play a role in the pathogenesis of B-NHL.
(4) More recently, the fourth translocation, t(3;14)(p14;q32), was detected when Streubel et al. 40 identified the FOXP1 gene at 3p14 as a new partner gene of the IgH gene. FOXP1 contains a DNA-binding domain known as forkhead domain with a biological function that is not fully understood. Further studies are thus needed to address whether the FOXP1 gene is involved in activation of the NF-kB signaling pathway or the other oncogenic pathways. A recent study found that this translocation involving the FOXP1 gene is also found in a subset of diffuse large B-cell lymphomas other than MALT lymphomas. 48 Chronic inflammation leads to activation of nuclear factor kappa B pathway via the antigen receptor signaling in mucosa-associated lymphoid tissue lymphoma cells
It has been suggested that antigen and the CD40 ligand act during T/B-cell interaction and play crucial roles in germinal center B-cell maturation. Several lines of evidence indicated that the auto-antigen as well as the CD40 ligand expressed by activated T cells may stimulate the growth of MALT lymphoma cells either directly or via paracrine mechanisms and that the antigen may make contributions to lymphoma pathogenesis. 85, 86 In addition, expression of costimulatory molecules, such as CD80 and CD86, was demonstrated in gastric MALT lymphoma cells, and it was found that the presence of the costimulatory molecule CD86 on the cells may promote T-cellmediated neoplastic B-cell growth. 87 It has been proposed that chronic antigenic stimulation by H. pylori triggers T-cell-mediated B-cell growth via activation of CD40 and NF-kB pathway early in the development of gastric MALT lymphoma. In this connection, Ho et al. 88 recently examined the effect of stably expressed MALT1 and API2-MALT1 in human B-cell lines on the NF-kB signaling pathway and elegantly demonstrated that cytoprotection mediated by NF-kB, once activated in a CD40-mediated immune response, is maintained and enhanced through deregulation of MALT1 or formation of API2-MALT1 fusion.
The NF-kB transcription factor family is essential for lymphocyte survival and activation. [89] [90] [91] [92] [93] [94] [95] [96] This family is composed of homodimers or heterodimers of five members (p50, p52, RelA, RelB or c-Rel) that share a conserved Rel homology domain for DNA binding. Recent studies have identified two distinct NF-kB signaling pathways: one is the 'classical' pathway and the other is the 'non-classical' pathway. [91] [92] [93] [94] The classical pathway, employing RelA/p50 dimers, performs a vital function in the immune, inflammatory and apoptotic responses. The nonclassical pathway, which employs RelB/p52 dimers, can lead to the expression of several chemokines that are required for organization of the secondary lymphoid organ in a classical IKK complex-independent manner. 91 Engagement of CD40, the B-cell activating-factor receptor and lymphotoxin-b receptor can activate not only the classical pathway but also the nonclassical pathway. 91, 94 Antigen receptor-stimulated NF-kB activation occurs via the classical NF-kB pathway. The last few years have witnessed a significant advance in our understanding of this signaling pathway through the identification of three key molecules, CARD-containing MAGUK1 (CARMA1), BCL10 and MALT1, all of which function downstream of the antigen receptor and upstream of the IKK complex. CARMA1, also known as CARD11 or BCL10-interacting membraneassociated guanylate kinase (MAGUK) protein 3 (BIMP3), was originally identified as a CARD-containing protein with the aid of protein database searches. [95] [96] [97] The members of the MAGUK family have several protein interaction domains, and they function as scaffolding proteins for clustering receptors and cytosolic signaling molecules. The N-terminal CARD domain of CARMA1 was found to interact with BCL10, which also contains an N-terminal CARD domain, whereas CARMA1 is mainly expressed in lymphoid tissues, and overexpression of CARMA1 results in NF-kB activation through the classical NF-kB pathway. 98, 99 A whole animal mutagenesis approach was used to investigate the role of CARMA1 in antigen receptor signaling. 100 One pedigree was found to harbor a single nucleotide change in the CARMA1 gene, a mutation that results in an amino-acid change in the N-terminal coiled-coil domain of CARMA1. The lymphocytes of this pedigree show evidence of the defects in antigen receptor signaling through the canonical NF-kB pathway. [101] [102] [103] Finally, the generation of CARMA1-deficient mice indicated that CARMA1 is essential for antigen receptor-and PKC-mediated proliferation and cytokine production in T and B cells. In addition, it is noteworthy that CARMA-deficient lymphocytes, similar to BCL10-or MALT1-deficient lymphocytes, showed defective proliferation when stimulated by CD40, suggesting that CARMA1-BCL10-MALT1 ternary complex integrates signals from CD40 to the IKK complex-mediated classical NF-kB pathway.
Despite the accumulation of our knowledge regarding the antigen receptor-stimulated NF-kB activation pathway, many questions remain unanswered. Two recent studies established that BCL10 promotes the antigen receptor-stimulated NF-kB activation through MALT1-and UBC13/Uev1A-dependent ubiquitination of NF-kB essential mudulator (NEMO)/IKK-g, but these studies disagreed regarding the mechanism underlying polyubiquitination. One study maintained that MALT1 functions as a ubiquitin ligase to mediate the 63K-linked ubiquitination of NEMO, 104 and the other study that TRAF6 and possibly TRAF2 function as a ubiquitin ligase of NEMO. 105 In the latter study, it was found that MALT1 greatly enhances the ability of TRAF6 to polyubiquitinate NEMO and catalyze the polyubiquitination chain, but that MALT1 alone had little influence on NEMO ubiquitination. Mutations within the TRAF6-binding sites of MALT1 resulted in elimination of the synergistic effect, and it was also found that recombinant TRAF6 from the baculovirusinfected insect cells could induce ubiquitination of NEMO and mediate IKK activation. More recently, it was suggested that API2-MALT1 fusion protein engages NF-kB in a TRAF6-independent manner. 106 Thus, the molecular mechanisms linking BCL10 and MALT1 to the IKK complex remain to be conclusively identified.
Two signaling pathways underlying the antiapoptotic effect by API2-MALT1 fusion protein
To examine whether API2-MALT1 fusion protein can exert an antiapoptotic function, we first employed a proteomic approach to identify API2-MALT1-binding proteins. 107 Three important regulators of apoptosis, Smac, HtrA2 and TRAF2, in addition to three other proteins, were identified as potential API2-MALT1-binding proteins. Smac is normally a mitochondrial protein and, like HtrA2, is released to the cytoplasm concurrent with cytochrome c release during apoptosis. 108, 109 We demonstrated that API2-MALT1 has indeed an antiapoptotic effect in UVinduced apoptosis by using HeLa cells stably expressing API2-MALT1, or control cells. We also provided experimental evidence that the fusion protein can inhibit the Smac-promoted apoptosis. 107 It can be assumed that API2-MALT1 can bypass the BCL10/ MALT1 cellular signaling pathway linked to NF-kB activation. Given that it has been found that several apoptotic inhibitors are upregulated by NF-kB activation, 110 it can also be assumed that API2-MALT1-induced NF-kB activation contributes to antiapoptotic action through upregulation of the apoptotic inhibitor genes. We recently provided evidence that API2-MALT1 in fact induces transcriptional activation of the API2 gene through the two NF-kB-binding elements. 111 As expression of API2-MALT1 is under the control of the API2 promoter in t(11;18)-carrying MALT lymphomas, our findings provide a strong indication that this fusion protein possesses a novel mechanism of selfactivation by upregulating its own expression, thus highlighting a positive feedback-loop pathway resulting in unremitting NFkB activation (Figure 1) . 111 Two recent studies also reported that API2-MALT1 confers resistance to UV-induced and p53-dependent apoptosis. 88, 112 Stoffel et al. demonstrated that antiapoptotic effect of API2-MALT1 depends on its activity of NF-kB activation.
On the basis of the results of our studies and others, we hypothesize that the antiapoptotic effect by API2-MALT1 may be mediated in one way by its interaction with apoptotic regulators and in another way by its self-activation resulting in unremitting NF-kB activation (Figure 1) . The continuous and sustained antiapoptotic stimuli driven by API2-MALT1 are most likely to play key roles in the pathogenesis of MALT lymphomas.
The other aspect of the function of MALT1; some implications for the immunohistological findings with respect to the BCL10 subcellular localization Recent studies regarding the biological function of MALT1 have mainly focused on the cytoplasmic events with respect to its involvement in NF-kB activation. 54, 55 To identify the other biological functions, we investigated the subcellular localization of MALT1 and found that MALT1 contains the nuclear export signal (NES) at its C-terminus and that it is localized predominantly in the cytoplasm. 113 Several immunohistological studies have demonstrated the subcellular localization of BCL10 in MALT lymphoma cases. [79] [80] [81] However, the mechanism of this localization of BCL10 is not yet fully understood, thus prompting us to examine the subcellular localization of BCL10 in COS7 cells, where we found that BCL10 was localized in both cytoplasm and nucleus. 113 Our examination of subcellular localization of both BCL10 and MALT1 in a co-transfection system found that these two proteins are colocalized in the cytoplasm only, but, intriguingly, that the NES-specific inhibitor, leptomycin B, treatment has changed their subcellular localization from the cytoplasm to the nucleus. This strongly indicates that MALT1 can export BCL10 from the nucleus to the cytoplasm. Based on our findings, we propose a model for the subcellular localization mechanism of BCL10 (Figure 2) , which may provide a satisfactory explanation for the results of the immunohistological studies of BCL10 in MALT lymphoma cases. In normal lymphocytes, BCL10 is localized in the cytoplasm because nuclear BCL10 is exported by MALT1. In t(11;18) MALT lymphoma, the amount of MALT1 proteins is reduced by half because of the reduction of the normal allele by half. As API2-MALT1 cannot export nuclear BCL10, the reduction of MALT1 proteins leads to less efficient export of BCL10, thus resulting in nuclear retention of BCL10. In t(1;14)
MALT lymphoma, overexpression of BCL10 results in nuclear retention because of a shortage of MALT1 relative to BCL10.
Conclusion and future perspectives
Recent studies have demonstrated that the three distinct translocations including t(11;18)(q21;q21), t(1;14)(p22;q32) and t(14;18)(q32;q21) that involve different genes utilize a common signaling pathway by ultimately targeting the same NF-kB signaling pathway. On the basis of experimental evidence, we hypothesize that an antiapoptotic effect by API2-MALT1 involved in t(11;18)(q21;q21) may be mediated by its interaction with apoptotic regulators on the one hand, and the NF-kB-mediated upregulation of apoptotic inhibitor genes on the other (Figure 1 ). Further studies are undoubtedly required to identify the pathogenesis of MALT lymphomas that lack the chromosomal translocations. It is possible that such MALT lymphomas may harbor subtle genetic alterations in the antigen receptor signaling pathway leading to NF-kB activation.
We have also demonstrated that MALT1 shuttles between the nucleus and cytoplasm in an NES-dependent manner and that MALT1 can regulate the subcellular location of BCL10. These new insights may provide a satisfactory explanation for the immunohistological studies of BCL10 in MALT lymphoma cases and should prompt further investigations to identify the novel oncogenic roles of BCL10 and MALT1 in the nucleus.
It is hoped that further studies will stimulate research into the development of therapeutic drugs that specifically inhibit the antigen receptor signaling pathway. CARMA1 and MALT1 represent promising molecular targets for therapeutic drug, because knockout mice in these molecules exhibit defects that are exclusively restricted to the antigen receptor signaling pathway. Recent studies also indicated that self-oligomerization of API2-MALT1 fusion protein causes deregulated ubiquitin ligase activity of MALT1, thereby leading to NF-kB activation. Thus, specific inhibitors of API2-MALT1 ubiquitin ligase would also be beneficial. Such two kinds of drugs can be expected to interfere, with controllable side effects, with the inappropriate growth and expansion of the lymphoma clone.
